HepaRegeniX GmbH has received over 20 million EUR from experienced investors in the life sciences field in two financing rounds. The series B financing was closed in early 2020. The support of specialized investors validates the company’s approach towards an innovative treatment approach for acute and chronic liver diseases.
Boehringer Ingelheim Venture Fund
The Boehringer Ingelheim Venture Fund (BIVF) was formed in March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science. The investment focus includes – but is not limited to immunomodulation, esp. immuno-oncology, tissue regeneration, new therapeutic modalities, e.g. gene therapy, cell-based therapeutics, ADC, and microbiome. This reflects BIVF’s interest in platform technologies and the extension of the current therapeutic area focus of Boehringer Ingelheim (BI) and demonstrates BIVF’s commitment to investigate new treatment modalities and technologies, beyond BI’s existing landscape, for the potential future benefit of patients. BIVF takes an active role with its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. The BIVF has € 100 million under management and supervises currently a portfolio of 18 active companies.
Novo Holdings A/S and Novo Seeds
Novo Seeds is the early stage investment arm of Novo Holdings A/S. Novo Seeds invests in European life science companies with transformative potential and takes an active role as investor, with a proven track record to create and build new companies. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. The company is the holding company in the Novo Group and responsible for managing the assets of the Foundation. Besides being the major shareholder in the Novo Group companies, including Novo Nordisk A/S and Novozymes A/S, Novo Holdings A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. For further information visit
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 560 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in a range of sectors, including software, hardware and life sciences/ chemistry. To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.
Coparion provides venture capital to accelerate momentum and growth. With a current active fund of EUR 225 million Coparion has the means to do so. Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparion team discerns potentials and opens up new perspectives. Coparion has the substance, tenacity and creativity required to mutually manage difficult situations successfully. Coparion only invests with co-investors. The fund invests up to EUR 10 million per company, usually in several financing rounds of EUR 0.5-3 million each. Investment focus is on German companies in the start-up and early growth phase. Coparion is based in Cologne and Berlin.